Nevena Krstić
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nevena Krstić has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Liebmann
Institute of Medical Genetics and Applied Genomics University Hospital Tübingen Tübingen Germany
1 shared publication - Andreas Dufke
Institute of Medical Genetics and Applied Genomics University of Tübingen Tübingen Germany
1 shared publication - Karl Oliver Kagan
Universitäts-Frauenklinik Tübingen
1 shared publication - Lena-Sophie Menig-Benzig
Institute of Medical Genetics and Applied Genomics University Hospital Tübingen Tübingen Germany
1 shared publication Markus Hoopmann
Department of Women's Health University of Tübingen Tübingen Germany
1 shared publication- Olaf Riess
Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
1 shared publication
Latest Publications
- Open Access
- 14 August 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (10) , 1648-1654
Prenatal Phenotypic Features of Five Fetal Cases With RNU4ATAC ‐Associated Microcephalic Osteodysplastic Primordial Dwarfism Type I
Objective: To present the prenatal sonographic features, genomic findings, and pregnancy outcomes of fetuses with biallelic pathogenic RNU4ATAC variants linked to microcephalic osteodysplastic primordial dwarfism type I (MOPD1). Methods: This retrospective case series includes five prenatal cases with MOPD1. Diagnoses were established by prenatal ultrasound and genetic testing. Genome sequencing (GS) or targeted exome sequencing (ES) detected the variants either prenatally or after termination of pregnancy (TOP). Clinical data including parental demographics, ultrasound findings, and pregnancy outcomes were collected. Results: All fetuses presented with consistent anomalies on ultrasound including intrauterine growth restriction (IUGR), microcephaly, agenesis of the corpus callosum (ACC), intracranial cysts, lissencephaly, and micrognathia. IUGR was the earliest anomaly detected in all five cases. Prenatal ultrasound findings suggestive of skeletal dysplasia were identified in one case. All cases carried biallelic pathogenic RNU4ATAC variants associated with MOPD1. TOP was chosen in four cases. One fetus was delivered at 39 + 1 weeks with genetic diagnosis confirmed at 27 weeks. Conclusion: IUGR, microcephaly and ACC can be detected in fetuses with MOPD1 at around 18 weeks of gestation. Interestingly, skeletal dysplasia was not a consistent prenatal finding. Variants in the non‐coding RNU4ATAC gene need to be detected by GS or targeted approaches beyond standard ES.
- 14 August 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (10) , 1648-1654
Open AccessPrenatal Phenotypic Features of Five Fetal Cases With RNU4ATAC ‐Associated Microcephalic Osteodysplastic Primordial Dwarfism Type I
Objective: To present the prenatal sonographic features, genomic findings, and pregnancy outcomes of fetuses with biallelic pathogenic RNU4ATAC variants linked to microcephalic osteodysplastic primordial dwarfism type I (MOPD1). Methods: This retrospective case series includes five prenatal cases with MOPD1. Diagnoses were established by prenatal ultrasound and genetic testing. Genome sequencing (GS) or targeted exome sequencing (ES) detected the variants either prenatally or after termination of pregnancy (TOP). Clinical data including parental demographics, ultrasound findings, and pregnancy outcomes were collected. Results: All fetuses presented with consistent anomalies on ultrasound including intrauterine growth restriction (IUGR), microcephaly, agenesis of the corpus callosum (ACC), intracranial cysts, lissencephaly, and micrognathia. IUGR was the earliest anomaly detected in all five cases. Prenatal ultrasound findings suggestive of skeletal dysplasia were identified in one case. All cases carried biallelic pathogenic RNU4ATAC variants associated with MOPD1. TOP was chosen in four cases. One fetus was delivered at 39 + 1 weeks with genetic diagnosis confirmed at 27 weeks. Conclusion: IUGR, microcephaly and ACC can be detected in fetuses with MOPD1 at around 18 weeks of gestation. Interestingly, skeletal dysplasia was not a consistent prenatal finding. Variants in the non‐coding RNU4ATAC gene need to be detected by GS or targeted approaches beyond standard ES.
- 25 January 2025
- Published by Elsevier in Seminars in Perinatology
- Vol. 49 (4) , 152025
The evolution of teratology: Historical perspectives and lessons learned
- 25 January 2025
- Published by Elsevier in Seminars in Perinatology
- Vol. 49 (4) , 152025
The evolution of teratology: Historical perspectives and lessons learned
- 21 October 2019
- Published by Wiley in Birth Defects Research
- Vol. 112 (4) , 321-331
Current landscape of prenatal genetic screening and testing
Pregnant patients should be offered the option of prenatal genetic screening and diagnostic testing. The type of screening and testing offered to a patient may depend on various factors including but not limited to age, family history, fetal findings, exposures, and patient preferences. Prenatal screening is available for a variety of genetic conditions including aneuploidy, congenital abnormalities, and carrier status. Diagnostic testing options include karyotype, prenatal microarray, as well as next‐generation sequencing. The various options differ in methodology, accuracy, timing and indication for testing, and information they provide. Given that the technologies related to prenatal testing are rapidly evolving and improving, the array of available screening and testing modalities are increasing. This article reviews the current offerings in prenatal screening and diagnosis.
- 21 October 2019
- Published by Wiley in Birth Defects Research
- Vol. 112 (4) , 321-331
Current landscape of prenatal genetic screening and testing
Pregnant patients should be offered the option of prenatal genetic screening and diagnostic testing. The type of screening and testing offered to a patient may depend on various factors including but not limited to age, family history, fetal findings, exposures, and patient preferences. Prenatal screening is available for a variety of genetic conditions including aneuploidy, congenital abnormalities, and carrier status. Diagnostic testing options include karyotype, prenatal microarray, as well as next‐generation sequencing. The various options differ in methodology, accuracy, timing and indication for testing, and information they provide. Given that the technologies related to prenatal testing are rapidly evolving and improving, the array of available screening and testing modalities are increasing. This article reviews the current offerings in prenatal screening and diagnosis.